IRIS
ELENA, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.945
AS - Asia 1.815
EU - Europa 1.453
SA - Sud America 267
Continente sconosciuto - Info sul continente non disponibili 188
AF - Africa 63
OC - Oceania 9
Totale 6.740
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.801
CN - Cina 795
SG - Singapore 388
IE - Irlanda 377
HK - Hong Kong 238
BR - Brasile 185
IT - Italia 182
RU - Federazione Russa 176
VN - Vietnam 174
FI - Finlandia 150
DE - Germania 148
UA - Ucraina 96
FR - Francia 94
GB - Regno Unito 75
CA - Canada 64
SE - Svezia 43
IN - India 36
AR - Argentina 33
BD - Bangladesh 28
MX - Messico 26
NL - Olanda 20
ZA - Sudafrica 20
BE - Belgio 18
IQ - Iraq 18
TR - Turchia 18
PL - Polonia 17
ES - Italia 14
PK - Pakistan 14
JP - Giappone 13
CO - Colombia 12
ID - Indonesia 11
IL - Israele 11
MA - Marocco 11
AT - Austria 10
CL - Cile 10
VE - Venezuela 9
EC - Ecuador 8
PY - Paraguay 8
SA - Arabia Saudita 8
AU - Australia 7
CR - Costa Rica 7
GT - Guatemala 7
NI - Nicaragua 7
SV - El Salvador 7
AZ - Azerbaigian 6
EE - Estonia 6
HN - Honduras 6
LT - Lituania 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
AM - Armenia 5
DZ - Algeria 5
GP - Guadalupe 5
LB - Libano 5
PH - Filippine 5
SC - Seychelles 5
TN - Tunisia 5
CW - ???statistics.table.value.countryCode.CW??? 4
EG - Egitto 4
JO - Giordania 4
KR - Corea 4
MY - Malesia 4
CZ - Repubblica Ceca 3
EU - Europa 3
GR - Grecia 3
JM - Giamaica 3
KE - Kenya 3
NP - Nepal 3
OM - Oman 3
TT - Trinidad e Tobago 3
AL - Albania 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RO - Romania 2
SN - Senegal 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
CH - Svizzera 1
DK - Danimarca 1
GD - Grenada 1
HU - Ungheria 1
IS - Islanda 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
Totale 6.553
Salva come PNG Salva come JPEG
Città #
Dublin 377
San Jose 303
Ashburn 235
Chandler 232
Hong Kong 231
Dallas 202
Singapore 196
Nanjing 163
Jacksonville 145
Beijing 141
Council Bluffs 136
Boardman 111
Ho Chi Minh City 70
Los Angeles 69
Nanchang 67
Ann Arbor 63
Princeton 58
Lauterbourg 56
Lawrence 56
Medford 55
Changsha 53
New York 52
Wilmington 50
Helsinki 48
Santa Clara 40
Hanoi 39
Hebei 38
Jiaxing 37
Munich 37
Shenyang 36
Pavia 31
Shanghai 27
Redondo Beach 26
Buffalo 25
Moscow 24
Orem 23
Hangzhou 22
Milan 22
Toronto 21
Turku 21
São Paulo 19
Brussels 18
Johannesburg 17
Montreal 17
Tianjin 15
Atlanta 14
Brooklyn 14
Rome 14
Belo Horizonte 13
Chennai 13
Frankfurt am Main 13
Warsaw 13
Woodbridge 13
Denver 12
Norwalk 12
Seattle 12
Chicago 11
Columbus 11
Houston 11
London 11
Mexico City 11
San Francisco 11
Manchester 10
The Dalles 10
Tokyo 10
Nuremberg 9
Haiphong 8
Jinan 8
Phoenix 8
Ankara 7
Guangzhou 7
Guatemala City 7
Managua 7
Naples 7
Vienna 7
Washington 7
Baghdad 6
Boston 6
Da Nang 6
Florence 6
Las Vegas 6
North Bergen 6
Padua 6
Philadelphia 6
Amsterdam 5
Asunción 5
Bến Tre 5
Charlotte 5
Fairfield 5
Falkenstein 5
Falls Church 5
Istanbul 5
Kunming 5
Pune 5
Stockholm 5
Tashkent 5
Verona 5
Amman 4
Baku 4
Campinas 4
Totale 4.170
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 203
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 197
Blast phase of essential thrombocythemia: A single center study. 160
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 160
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 157
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 156
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 152
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 146
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 142
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome 141
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 136
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 131
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 129
Clinical significance of somatic mutation in unexplained blood cytopenia 129
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia 129
Somatic mutations of calreticulin in myeloproliferative neoplasms 123
A geno-clinical decision model for the diagnosis of myelodysplastic syndromes 121
Particulate cytoplasmic structures with high concentration of ubiquitin-proteasome accumulate in myeloid neoplasms 121
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 121
Relationship between clone metrics and clinical outcome in clonal cytopenia 120
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 117
The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications 111
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 111
Incidence and Prognosis of Clonal Hematopoiesis in patients with Chronic Idiopathic Neutropenia 111
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 110
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 109
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 107
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts 106
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 102
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 102
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 102
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 100
Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications 99
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 99
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 95
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes 94
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. 94
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 93
‘Real-life’ study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis 93
Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia 93
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 93
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 92
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 90
Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis 89
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions 89
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification 89
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. 86
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 85
A cross‐sectional study on quality of life in adult indolent systemic mastocytosis and its association with cutaneous involvement 83
Mutational status of myeloproliferative neoplasms. 82
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 80
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 79
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis 79
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 75
Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry 67
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry 66
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: A real clinical problem? 65
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. 65
The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. 65
Validation of cytogenetic-based risk stratification in primary myelofibrosis. 63
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry 58
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 55
Telangiectasia macularis eruptiva perstans: a neglected type of mastocytosis with exclusively cutaneous involvement? A case series 52
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis 43
Unusual widespread cutaneous eruption due to nilotinib therapy for chronic myeloid leukemia 28
Totale 6.740
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.291
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.291
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022272 0 0 0 0 5 7 4 16 13 21 40 166
2022/2023836 77 60 5 43 80 61 0 38 423 6 30 13
2023/2024368 53 59 21 23 27 100 1 29 3 5 8 39
2024/2025947 22 71 26 21 28 63 62 67 211 34 126 216
2025/20262.330 152 204 283 284 252 90 441 74 233 186 57 74
2026/2027735 43 128 154 280 130 0 0 0 0 0 0 0
Totale 6.740